Education
About Us
Working with TipRanks
Follow Us
ImmunityBio (IBRX)
NASDAQ:IBRX
IBRX Stock Chart & Stats
$2.24
-$0.11(-4.03%)
At close: 4:00 PM EST
$2.24
-$0.11(-4.03%)
Day’s Range― - ―
52-Week Range$1.83 - $4.27
Previous CloseN/A
Volume1.20M
Average Volume (3M)12.29M
Market Cap
$2.17B
Enterprise Value$2.93B
Total Cash (Recent Filing)$153.66M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.17
Next Earnings
Mar 03, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding984,965,150
10 Day Avg. Volume7,930,064
30 Day Avg. Volume12,285,005
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-3.66
Price to Sales (P/S)121.07
P/FCF Ratio-4.48
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue35.53
Enterprise Value/Gross Profit37.49
Enterprise Value/Ebitda-12.61
Forecast
1Y Price Target
$7.33Price Target Upside227.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial PerformanceANKTIVA's strong early commercial traction in BCG-unresponsive CIS NMIBC with unit sales up 467% highlights its expanding adoption.
Market ExpansionEuropean conditional approval meaningfully expands the commercial runway while also reinforcing regulatory confidence in the underlying immunologic mechanism.
Regulatory ApprovalThe European Medicines Agency has issued a positive opinion recommending conditional marketing authorization for ANKTIVA in combination with BCG for patients with BCG unresponsive non muscle invasive bladder cancer.
Bears Say
Regulatory ChallengesThe conditional nature of the authorization underscores the importance of post marketing commitments, prompting questions around the timing and scope of long term.
ImmunityBio News
IBRX FAQ
What was ImmunityBio’s price range in the past 12 months?
ImmunityBio lowest stock price was $1.83 and its highest was $4.27 in the past 12 months.
What is ImmunityBio’s market cap?
ImmunityBio’s market cap is $2.17B.
When is ImmunityBio’s upcoming earnings report date?
ImmunityBio’s upcoming earnings report date is Mar 03, 2026 which is in 52 days.
How were ImmunityBio’s earnings last quarter?
ImmunityBio released its earnings results on Nov 04, 2025. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.107 by $0.037.
Is ImmunityBio overvalued?
According to Wall Street analysts ImmunityBio’s price is currently Undervalued.
Does ImmunityBio pay dividends?
ImmunityBio does not currently pay dividends.
What is ImmunityBio’s EPS estimate?
ImmunityBio’s EPS estimate is -0.11.
How many shares outstanding does ImmunityBio have?
ImmunityBio has 984,965,150 shares outstanding.
What happened to ImmunityBio’s price movement after its last earnings report?
ImmunityBio reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.107. Following the earnings report the stock price went down -7.965%.
Which hedge fund is a major shareholder of ImmunityBio?
Currently, no hedge funds are holding shares in IBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImmunityBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.33 (227.23% Upside)
$7.33 (227.23% Upside)
Blogger Sentiment
Bullish
IBRX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
42.36%
Trailing 12-Months
Company Description
ImmunityBio
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
IBRX Stock 12 Month Forecast
Average Price Target
$7.33
▲(227.23% Upside)
Technical Analysis
Catalyst Pharma
―
Immunovant
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―
Ownership Overview
66.42% Insiders
3.35% Mutual Funds
3.48% Other Institutional Investors
21.85% Public Companies and Individual Investors